Cencora, Inc.
No SEC Form 4 filings for $COR in the last 30 days.
Cencora (NYSE:COR) reported Q3 results on its earnings call. U.S. Healthcare Solutions operating income rose 16% to $966 million, and International revenue grew 6% to $7.7 billion with operating income up 21% to $166 million. The company expects fiscal 2026 consolidated adjusted operating income growth of 13% to 14%, and said OneOncology integration is modestly ahead of initial expectations.
Cencora reported Q3 2026 results driven by specialty pharmaceutical strength in health systems and physician practices, with its MSO platforms (including OneOncology and RCA) ahead of expectations. Adjusted EPS guidance for fiscal 2026 was raised to $17.75 to $17.95. The company completed $1 billion of share repurchases, expects U.S. Healthcare Solutions revenue in the lower half of 4% to 6% growth, and cited a $0.35 EPS headwind from the pending MWI Animal Health merger.
Cencora (COR) reported Q3 sales of $84.754B, up 5.1% year over year and above the $84.315B consensus, driven by demand across its distribution networks. Gross profit rose 24.1% to $3.6B and operating income rose 29.1% to $1.1B. It raised FY2026 adjusted EPS guidance to $17.75-$17.95 and affirmed sales guidance. GLP-1 mix weighed on margins.
Over the past 7 days, alphai's AI scored 6 news stories mentioning COR (Cencora, Inc.). Coverage has skewed bullish: 4 bullish, 2 neutral, and 0 bearish.
Recent COR coverage spans earnings, corporate actions and insider activity.
Guidance and integration/EPS framing around OneOncology, plus a quantified 2027 headwind from MWI/Covetrus, are likely to drive near-term estimate revisions and positioning.
Guidance raise plus buybacks and specialty strength are likely to support near-term estimates and sentiment, while the MWI Animal Health merger and 340B/IRA policy monitoring add uncertainty.
Guidance raise plus margin headwind from GLP-1 mix creates a two-sided setup for COR, with near-term focus on specialty growth and gross margin trajectory.
The filing signals updated counterparty participation and facility terms under Cencora’s performance guarantee structure, which can affect funding/credit risk optics but lacks disclosed economics in the excerpt.
Raised adjusted EPS guidance alongside Q3 results suggests improved earnings trajectory, but higher operating expenses and interest costs tied to the OneOncology acquisition remain key watch items.
alphai scores every news story that mentions COR with an AI model for sentiment and relevance, and aggregates insider trades from Cencora, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cencora (NYSE:COR) reported Q3 results on its earnings call. U.S. Healthcare Solutions operating income rose 16% to $966 million, and International revenue grew 6% to $7.7 billion with operating income up 21% to $166 million. The company expects fiscal 2026 consolidated adjusted operating income growth of 13% to 14%, and said OneOncology integration is modestly ahead of initial expectations.
6 min readCencora reported Q3 2026 results driven by specialty pharmaceutical strength in health systems and physician practices, with its MSO platforms (including OneOncology and RCA) ahead of expectations. Adjusted EPS guidance for fiscal 2026 was raised to $17.75 to $17.95. The company completed $1 billion of share repurchases, expects U.S. Healthcare Solutions revenue in the lower half of 4% to 6% growth, and cited a $0.35 EPS headwind from the pending MWI Animal Health merger.
7 min readCencora (COR) reported Q3 sales of $84.754B, up 5.1% year over year and above the $84.315B consensus, driven by demand across its distribution networks. Gross profit rose 24.1% to $3.6B and operating income rose 29.1% to $1.1B. It raised FY2026 adjusted EPS guidance to $17.75-$17.95 and affirmed sales guidance. GLP-1 mix weighed on margins.
6 min readCencora, Inc. (COR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 3 tm2621845d1_ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 EXECUTION VERSION OMNIBUS AMENDMENT This OMNIBUS AMENDMENT, dated as of July 31, 2026 (this “ Amendment ”) is (1) THE TWENTY-THIRD AMENDMENT TO AMENDED AND RESTATED RECEIVABLES PURCHASE AGREEMENT, among AMERISOURCE RECEIV
4 min readCencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q32026.htm EX-99.1 Document Exhibit 99.1 CENCORA REPORTS FISCAL 2026 THIRD QUARTER RESULTS Revenue of $84.8 billion for the Third Quarter, a 5.1 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.94 and Adjusted Diluted EPS of $4.48 Adjusted
4 min readReuters reports the FTC is reviewing a proposed $3.5 billion deal combining Cencora’s MWI Animal Health with Covetrus, after Bloomberg said the agency issued information requests to Covetrus customers and rivals. The requests cover effects on veterinary product availability and practice-management software. Cencora said it would sell MWI Animal Health to Covetrus in February.
3 min readCencora (COR) will report Q3 fiscal 2026 earnings Aug. 5 before market open. The prior quarter saw a 1.04% earnings miss. Zacks Consensus estimates call for revenue of $84.89B (+5.2% YoY) and EPS of $4.37 (+9.3% YoY). The article cites an Earnings ESP of +1.37% and Zacks Rank #2, suggesting a beat is likely.
4 min readTyler Lauren M purchased 550 shares of Cencora, Inc. (COR) at $270.23 ($0.15M total) on 2026-06-22.
2 min readDURCAN DERMOT MARK purchased 4,000 shares of Cencora, Inc. (COR) at $274.19 ($1.10M total) on 2026-06-18.
2 min readCencora, Inc. (COR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001140859 0001140859 2026-06-10 2026-06-10 0001140859 us-gaap:CommonStockMember 2026-06-10 2026-06-10 0001140859 COR:Sec2.875SeniorNotesDue2028Member 2026-06-10 2026-06-10 0001140859 COR:Sec3.625SeniorNotesDue2032Member 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso421
3 min read
